This paper uses a General Health Policy Model to determine the costeffectiveness of an experimental behavioral program for patients with chronic obstructive pulmonary disease (COPD). Patients were randomly assigned to either ex'perimental or control groups, and only those in the experimental groups were given the behavioral strategies. Health status information was collected over 18 months, and the Health Policy Model translated program outcomes into well-year equivalents. At the end of the program, greater im-. " provements in health status were observed in the experimental subjects, and a : " total of 4.41 well-years were produced. Costs of the program were gathered on a per-year basis using an administrative perspective. Both costs and health effects were discounted to present value using a 5% discount rate. Dividing costs by effects, the COPD program produced well-years at a unit cost of $24,256. Comparing the cost-utility figure to those of other health care programs using the General Health Policy Model, the behavioral program appears reasonably cost-effectlve as an adjunct therapy for patients suffering from COPD.
AND CATHEIRIN-EJ. ATKLNS, PHD* This paper uses a General Health Policy Model to determine the costeffectiveness of an experimental behavioral program for patients with chronic obstructive pulmonary disease (COPD). Patients were randomly assigned to either ex'perimental or control groups, and only those in the experimental groups were given the behavioral strategies. Health status information was collected over 18 months, and the Health Policy Model translated program outcomes into well-year equivalents. At the end of the program, greater im-. " provements in health status were observed in the experimental subjects, and a : " total of 4.41 well-years were produced. Costs of the program were gathered on a per-year basis using an administrative perspective. Both costs and health effects were discounted to present value using a 5% discount rate. Dividing costs by effects, the COPD program produced well-years at a unit cost of $24,256. Comparing the cost-utility figure to those of other health care programs using the General Health Policy Model, the behavioral program appears reasonably cost-effectlve as an adjunct therapy for patients suffering from COPD. In an earlier paper we reported that the tion. During this assessment, the patient three experimental groups differed signifiwas given a variety of psychologic, health canfly from the two control groups on a " •" 'i : status, and physiologic tests. Physiologic variety of measures. 2°However, on most : tests included the assessment of pulmonary -measures, the experimental groups did not . function through spirometry and graded differ from one another. For the purposes exercise tests on a treadmill. Of particular of this paper, data from the three experiimportance for this paper is the assessment mental groups were combined as were data of health status. The methodology for the for the two control groups. Extensive assessment of health status is described in analyses demonstrated that all differences the next section, on outcome measures behveen the treated Each patient was assigned an exercise and control groups were nonsignificant prescription based upon maximum miles prior to the interventions. At the 3-month per hour he or she obtained on the treadfollow-up, those in the experimental " " mill. All assignments were made in terms groups walked significantly more, showed of walking at defined speeds, significant improvements in exercise tolGroups erance, and reported greater personal expectations for completing the activity3°W e randomly assigned patients to one of Most important, participants in the exfive groups. In three groups behavioral perimental groups showed significant benefits, as measured by the Health Status effectiveness of the program. The costIndex, relative to the participants in the effectiveness ratio can be used to compare control groups, the relative value of different programs, thereby providing a common metric for the Health Status Effectiveness Measurement comparison of programs with different specific objectives. One of the major outcome measures was Cost-effectiveness analysis usually rea Health Status Index (HSI)._-_4Although
quires discounting costs and effects bea variety of measures have been used to cause money spent now is worth more than evaluate methods for increasing cornmoney spent in the future. One hundred pliance, few studies have attempted to link dollars today will become more than 100 • the interventions to health outcomes. The dollars next year if it were put in a bank or a purpose ofthe HSI is to show the output of wise investment. When purchasing a fu--a program in terms of the equivalents of turebenefit, itis important to consider both "years of life it produces. The years of life the expected value of the money in the figure is adjusted for diminished quality of future and the decreased value of the bene-.. life produced by disease and disability. For fit given the delay before it is delivered. ."
example, a disease that reduces quality of The choice of a discount rate is a matter of .... shown that the mean Quality of Well-being which is associated with a weight derived value over 4 days is more reliable than the from community surveys to reflect the sovalue obtained on any one day. Therefore, cia] preference or utility for the state on a Quality of Well-being data were obtained . scale ranging from 0 (dead) to 1.0 (for opfor the 4 days preceding each visit, and the .:. timum functioning). Thus, a score of 0.64 mean value across the 4 days was used for -.
-:. suggests that an individual was in an oball calculations. Quality of Well-being : " servable state for which the mean societal scores prior to treatment were compared . preference is 64% of the distance between across groups using a one-way analysis of optimum functioning and death. A person variance. This analysis demonstrated that " : remaining in this state for 1 year would groups did not differ prior to the intervenhave lost 0.36 well-years. Prognoses in the tions (F value). For all other analyses, model are defined by transitions among changes in well-being scores from the iniobservable states over time. These are reptial visit were used. resented in all calculations of well-years. 2_ Differences in well-being scores beThe complex assumptions that underlie tween the experimental and control groups this model are given in other papers? 2-2e are displayed in Fig. 1 , which demonUsing the HSI system, it is possible to strates that the experimental and control estimate the number of well-year equivagroups differed by the first follow-up pe-]ents a program produces. Dividing the riod(F1/65= 9.98,P<0.002). ferenceovera 3-monthperiod.The final column shows the well-year yield for that period, which is calculated by obtaining tolerance was 0.40 (P < 0.01). Following the product of the difference in well-being the 3-month assessment, the experimental between treated and control groups times and control groups continued to differ at the number ofpatients in the experimental . each assessment period. However, by the groups and multiplying that produet by the last follow-up, the differences were only proportion of the year the assessment rep .... marginally statistically significant. The reresents. For example, at the 3-month duction in statistical significance results follow-up, the treated and control groups • " ' :
• ' -. from increased variability in both groups differed by 0.076 units of well-being. This across follow-up sessions, value times the 42 patients included in the Table 1 summarizes the observed wellexperimental groups (and ignoring the 28 year benefits for the experiment. The first control group patients) yields 3.19. Howcolumn shows the follow-up periods. The ever, this value is obtained only after one second column shows the change in wellquarter of 1 year. To estimate the well-year being score for the treated group, while the production, multiply 3.19 by 0.25 to obtain third column shows the mean change in 0.80, Similar assessments were made for well-being for the control subjects. The the 6-month, 12-month, and 18-month fourth column shows the difference befollow-ups. The total well-year production well-years gives a total well-year producIt is important that the benefits of a betion of 6.66. The discounted figure for this havioral program should continue beyond assumption (with the final section disa final assessment period. An important counted at 5% for 3.5 ),ears) equals 6.15 implication of the Health Decision Model well-years (Table 1) . While analyses treat is that it tracks patients over the remainder health status as a constant, in fact it varies of their life expectancy. In other words, we naturally. The.assumpti0ns we have prewould expect benefits to continue to acsented are for illustrative purposes only. crue far beyond the treatment period.
We have observed an estimated 4.41 However, we are hesitant to estimate benwe/l-years of benefit in the study and efits we have not observed. Therefore, fumight expect an additional 1. considered it inappropriate to include later 1) direct costs of treatment; 2) indirect health costs while ignoring later costs of costs; and 3) averted hospitalization housing, food, etc. In other words, this apcharges. The values for the third category proach oddly singles out for inclusion reedwere calculated as follows:
ical care costs of extended life. Second, including extended life costs ignores the H = (Ac x Ne x C) -(At x Nt x C) effects of continued life upon possible where H is averted hospital charges; Ac is economic productivity. These arguments control groups: average numberofdaysper . are discussed in more detail in a recent person spent hospitalized during study pcpaper by Warner,'_e in which including exriod; Ne is control groups: number of subtended life medical costs is described as a jects; C is charges per day for semiprivate "flaw" in cost-effectiveness methodology. hospital room plus usual ancillary services Total project costs amounted to for COPD patients; At is treated groups:
$108,516. However, this analysis includes average number of days per person spent only the costs directed toward treatment hospitalized during study period; Nt is group subjects. As with effects, the final treated groups: number of subjects, cost figure is discounted to present value. The number of hospitalizations was deDiscounting is performed by dividing each termined by interview at the follow-up asyear's costs or effects by the factor (1 + r)n, sessments. Hospitalization charges were where r represents the interest rate (disestimated using the average charges per count factor) and n the number of years individual interviewed at the final followafter the initial assessment. Applying a 59'o up. The averted hospital costs represent discount factor to total costs gives a present the average difference in charges to an invalue of $69,350 (see the cost breakdown in dividual as a result of the intervention. Table 2 ). These calculations excluded dropouts. We Table 3 shows the costs used in the senassume that dropouts in the experimental sitivity analysis. The range of costs was and control groups would have equal hoschosen to include expenditures both above pitalization charges and that differences and below those actually allotted during would cancel. Given that charges for the project (i.e., an estimation ofcost error). treated patients were less than those of The higher costs could represent normal control subjects in the nondropouts, the billing charges. For example, under asassumption of no differences for the dropsumption 1, professional fees are higher than those actually paid during the study. For example, staff preparatory time and Professional salaries incurred during the clerical costs for project startup would be study (base case) were below prevailing spread over a larger patientpopulation and rates for physician/psychologist.
Cona longer period of time. Also, indirect costs versely, assumption 2 is a simulation of would be spread among more than one : costs had the behavioral interventions treatment, or project, so that the proportion been incorporated in regular clinical care.
to direct costs of the behavioral treatment is reduced. A 15%overhead rate was chosen tality, and simultaneously expresses risks for this simulation. The total costs for each and benefits. of the two assumptions were discounted at
The derivation of the denominator is 5% in the same manner actual costs were given in the Appendix. The numerator is discounted. As Table 3 shows, the present adapted from Weinstein and Stason.27The value of costs used in the sensitivity only difference is that eosts associated with analysis ranged from $162,714 to 872,157. treating other illnesses necessitated by extended life are not included. 2_ Cost-effectiveness of the Study Various discount rates were also applied to the different cost and effectiveness figCost-effectiveness of a medial program ures to evaluate their impact upon the can be defined as:
cost-effectiveness ratio. Values were calcu-C/E = Crx + Cmorb lated using rates of 0%, 5%, and 10%, with E 5% representing the base case.
• where C/E is cost effectiveness; Crx is in-
The final cost-effectiveness figure for the cremental costs of behavioral programs;
COPD project, as shown in Table 4 , is Cmorb is savings in treatment cost due to $24,256 per well-year. This is found in the reduced morbidity (could be positive or cost-effectiveness portion of According to this analysis, the behavioral dialysis, known to be an effective medical programs for COPD patients are toward treatxnent for its life-prolonging capacity, the cost-effectiveness end of the costs more than $50,000 to produce a continuum. well-year.
One of the benefits of the The assumptions made in the current decision-analysis approach is that it can analysis may be conservative for several compare programs with fundamentally difreasons. First, the costs of a research study TOEVSETAL.
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are necessarily higher than the costs of against alternative increases in health care regular clinical care. In a previous analysis expenditures. Ultimately, the use of costthat considered the cost-effectiveness of effectiveness analysis should go beyond behavioral programs in clinical care of the simple justification that services COPD patients, we found the costs to be should be reimbursed. The major thaiconsiderably lower. 2°Second, the costlenges are in the selection between corneffectiveness estimates may be conservapeting alternatives. tive because we did not project benefits far
In summary, we feel that our data are into the future. We are reluctant to add encouraging. Despite some limitations and long-term benefits to our analysis because complex assumptions, we feel that bewe have not observed them.
havioral programs have been demonOur analysis clearly has some limitastrated to be cost-effective as an adjunct tions. First, it is based on a small study with therapy for COPD patients. a small group of COPD patients. The patients may not be representative of COPD Acknowledgments patients in general, and our conclusions may be restricted to this sample. Second, 
